Functional PET imaging using a PARP inhibitor (PARPi) analog may serve as an early, dynamic biomarker of response to PARPi therapy in high-grade serous ovarian cancer. Clinically, this could help to rapidly identify PARPi nonresponders, thereby maximizing efficacy and avoiding toxicities of futile treatments.

See related article by Pantel et al., p. xxx

This content is only available via PDF.
You do not currently have access to this content.